Two studies described the use of anti-EGFR TKIs in a population of NSCLC patients with an activating mutation of the related gene, and found an incidence of use between 77.8% and 85.0% (Figure 2b) [25,41]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.